SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77328.19
516.33 (-0.66%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Health X Platform Ltd.	Q V PT	947 Small Cap	297.75 (2.41%)	N/A	3.5	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Fischer Medical Ventures Ltd.	Q V PT	2,451 Small Cap	37.45 (-0.87%)	N/A	7.62	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	3B Blackbio Dx Ltd.	Q V PT	1,111 Small Cap	1,294.50 (-0.55%)	21.74	3.57	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Max Healthcare Institute Ltd.	Q V PT	98,526 Mid Cap	1,012.35 (-0.27%)	69.42	9.51	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Indegene Ltd.	Q V+ PT	12,759 Small Cap	529.65 (-0.28%)	31.81	4.07	34.59	31.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Acutaas Chemicals Ltd.	Q V+ PT	22,377 Small Cap	2,733.15 (0.42%)	61.11	13.41	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Rubicon Research Ltd.	Q V+ PT	15,761 Small Cap	954.70 (0.29%)	94.08	12.19	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Yatharth Hospital & Trauma Care Services Ltd.	Q V+ PT	8,312 Small Cap	862.60 (4.86%)	88.84	5.21	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Dr. Agarwals Health Care Ltd.	Q V PT	14,404 Small Cap	454.45 (0.70%)	114.27	7.29	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Sigachi Industries Ltd.	Q V+ PT	841 Small Cap	22.01 (4.96%)	N/A	1.78	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Anthem Biosciences Ltd.	Q V+ PT	44,069 Mid Cap	784.55 (0.73%)	87.06	14.86	23.81	40.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Marksans Pharma Ltd.	Q V PT	8,968 Small Cap	197.90 (-2.58%)	36.4	5.76	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Eris Lifesciences Ltd.	Q V PT	19,212 Small Cap	1,386.75 (0.22%)	44.5	5.3	21.92	3.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,817 Small Cap	1,751.25 (2.10%)	32.13	5.92	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Innova Captab Ltd.	Q V PT	5,010 Small Cap	875.45 (1.44%)	59.86	5.65	20.74	22.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Poly Medicure Ltd.	Q V PT	16,736 Small Cap	1,651.20 (-1.69%)	48.93	5.64	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,557 Small Cap	95.47 (6.85%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Concord Biotech Ltd.	Q V PT	12,294 Small Cap	1,175.15 (-1.84%)	39.34	6.5	18.56	18.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Natco Pharma Ltd.	Q V PT	21,028 Small Cap	1,174 (1.72%)	13.5	2.39	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Windlas Biotech Ltd.	Q V PT	1,732 Small Cap	820.55 (-4.24%)	25.96	3.15	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Jupiter Life Line Hospitals Ltd.	Q V PT	8,192 Small Cap	1,249.40 (-0.78%)	43.9	5.26	18.02	36.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	34,551 Small Cap	2,151.90 (0.49%)	47.5	8.85	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Sai Life Sciences Ltd.	Q V+ PT	23,680 Small Cap	1,116.85 (2.55%)	72	9.86	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,465 Small Cap	5,101.30 (0.74%)	35.3	7.43	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Syncom Formulations (India) Ltd.	Q V PT	1,383 Small Cap	14.71 (-1.61%)	20.06	3.5	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Caplin Point Laboratories Ltd.	Q V PT	14,118 Small Cap	1,857.35 (-0.47%)	23	4.25	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Supriya Lifescience Ltd.	Q V PT	5,697 Small Cap	707.80 (1.06%)	30.75	5.03	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Global Health Ltd.	Q V PT	32,278 Small Cap	1,200.60 (-1.14%)	69.34	8.32	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Gufic Biosciences Ltd.	Q V PT	3,008 Small Cap	300 (0.93%)	59.52	4.67	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Anuh Pharma Ltd.	Q V PT	843 Small Cap	84.15 (1.45%)	20.17	2.48	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Metropolis Health.	550.30	8.83%
Shree Ganesh Remed.	530.60	8.65%
KMC Speciality Hosp	95.47	6.85%
Guj. Kidney & Super	139.85	6.84%
Nectar Lifesciences	14.39	5.89%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Indoco Remedies	228.20	-9.17%
Windlas Biotech	820.55	-4.24%
Panacea Biotec	388.15	-4.16%
Fermenta Biotech	288.70	-4.07%
Lupin	2,377.90	-3.33%

News about Top Pharma Companies in India

May, 2026

Innova Captab - Quaterly Results

The Sales for the quarter ended March 2026 of Rs. 3582.77 millions rose by 47.73% from Rs. 2425.22 millions.Modest increase of 23.57% in the Net Profit was reported from. 171.25 millions to Rs. 211.62 millions.Operating profit surged to 413.19 millions from the corresponding previous quarter of 325.36 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	3582.77	2425.22	47.73	12988.14	9580.61	35.57	12988.14	9580.61	35.57
Other Income	26.80	43.56	-38.48	132.43	167.75	-21.06	132.43	167.75	-21.06
PBIDT	413.19	325.36	26.99	1646.10	1390.74	18.36	1646.10	1390.74	18.36
Interest	39.81	18.69	113.00	154.21	21.68	611.30	154.21	21.68	611.30
PBDT	373.38	306.67	21.75	1491.89	1369.06	8.97	1491.89	1369.06	8.97
Depreciation	94.03	78.12	20.37	373.67	170.15	119.61	373.67	170.15	119.61
PBT	279.35	228.55	22.23	1118.22	1198.91	-6.73	1118.22	1198.91	-6.73
TAX	67.73	57.30	18.20	281.30	304.21	-7.53	281.30	304.21	-7.53
Deferred Tax	58.38	29.89	95.32	103.65	84.21	23.09	103.65	84.21	23.09
PAT	211.62	171.25	23.57	836.92	894.70	-6.46	836.92	894.70	-6.46
Equity	572.25	572.25	0.00	572.25	572.25	0.00	572.25	572.25	0.00
PBIDTM(%)	11.53	13.42	-14.04	12.67	14.52	-12.69	12.67	14.52	-12.69

May, 2026

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

May, 2026

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

May, 2026

Max Healthcare Institute informs about allotment of equity shares

Max Healthcare Institute has informed that Nomination & Remuneration Committee (‘NRC’) of the Company on May 1, 2026, at 6.56 pm (IST), has approved the allotment of 51,287 equity shares having face value of ?10 each, fully paid-up, to eligible employees, consequent to the exercise of vested stock options in accordance with Max Healthcare Institute Limited - Employee Stock Option Scheme 2022. Consequent to the above allotment, the paid-up equity share capital of the Company stands increased from 973,19,25,020 to 973,24,37,890. In terms of regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the requisite details of equity shares allotted as above are enclosed as Annexure. This disclosure will also be hosted on Company's website: www.maxhealthcare.in.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Acutaas Chemicals - Quaterly Results

The sales surged to Rs. 4217.72 millions, up 38.67% for the March 2026 quarter as against Rs. 3041.61 millions during the corresponding quarter previous year.The Net Profit of the company vaulted to 118.10% to Rs. 1370.71 millions from Rs. 628.48 millions in the previous quarter.Operating Profit saw a handsome growth to 1957.63 millions from 897.52 millions in the quarter ended March 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	4217.72	3041.61	38.67	13237.92	9898.35	33.74	13237.92	9898.35	33.74
Other Income	145.46	56.94	155.46	458.78	183.36	150.21	458.78	183.36	150.21
PBIDT	1957.63	897.52	118.12	5288.83	2434.78	117.22	5288.83	2434.78	117.22
Interest	10.72	3.83	179.90	30.77	58.57	-47.46	30.77	58.57	-47.46
PBDT	1946.91	893.69	117.85	5258.06	2376.21	121.28	5258.06	2376.21	121.28
Depreciation	88.30	65.56	34.69	330.32	240.45	37.38	330.32	240.45	37.38
PBT	1858.61	828.13	124.43	4927.74	2135.76	130.73	4927.74	2135.76	130.73
TAX	487.90	199.65	144.38	1265.99	540.29	134.32	1265.99	540.29	134.32
Deferred Tax	17.36	47.36	-63.34	111.09	70.58	57.40	111.09	70.58	57.40
PAT	1370.71	628.48	118.10	3661.75	1595.47	129.51	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	46.41	29.51	57.29	39.95	24.60	62.42	39.95	24.60	62.42

Apr, 2026

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

The total consolidated income of the company increased by 29.83% at Rs 1014.20 crore for Q4FY26

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Health X Platform Ltd.	947 Crore
2	Fischer Medical Ventures Ltd.	2,451 Crore
3	3B Blackbio Dx Ltd.	1,111 Crore
4	Max Healthcare Institute Ltd.	98,526 Crore
5	Indegene Ltd.	12,759 Crore
6	Acutaas Chemicals Ltd.	22,377 Crore
7	Rubicon Research Ltd.	15,761 Crore
8	Yatharth Hospital & Trauma Care Services Ltd.	8,312 Crore
9	Dr. Agarwals Health Care Ltd.	14,404 Crore
10	Sigachi Industries Ltd.	841 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,661	56,654	37.17	12.91	26.02	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	65.25	16.32	36.87	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	24.45
Lupin Ltd. (M)	Somewhat Good	2,378	1,08,721	20.39	4.84	11.79	20.83
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	110
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,364	66,722	67.00
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	40.02
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,380	1,48,251	37.62
Gland Pharma Ltd. (S)	Very Good	1,904	31,377	34.73
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	17.81
Mankind Pharma Ltd. (M)	Very Good	2,427	1,00,200	58.82	6.28	35.25	14.65
Laurus Labs Ltd. (M)	Very Good	1,229	66,373	74.68	12.52	37.46	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,032	37,883	35.87	8.37	24.25	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	939	94,475	19.13	3.60	11.91	30.57
Cipla Ltd. (L)	Very Good	1,348	1,08,865	23.95	3.24	14.44	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,847	4,43,229	40.61	5.46	22.21	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,293	1,07,942	19.38	2.90	11.65	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,551	47.50	8.85	30.00	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Innova Captab - Quaterly Results

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Max Healthcare Institute informs about allotment of equity shares

Acutaas Chemicals - Quaterly Results

Indegene gains even after reporting 32% fall in Q4 consolidated net profit

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.